دورية أكاديمية
أعرض في EDS

Efficacy and safety of preemptive therapy for cytomegalovirus end-organ disease in people living with HIV: a systematic review and meta-analysis.

التفاصيل البيبلوغرافية
العنوان: Efficacy and safety of preemptive therapy for cytomegalovirus end-organ disease in people living with HIV: a systematic review and meta-analysis.
المؤلفون: Díaz-Brochero C; Universidad Nacional de Colombia, School of Medicine, Department of Internal Medicine, Bogotá, Colombia. Electronic address: cdiazbr@unal.edu.co., Nocua-Báez LC; Universidad Nacional de Colombia, School of Medicine, Department of Internal Medicine, Bogotá, Colombia; Hospital Universitario Nacional de Colombia, Infectious Diseases Unit, Bogotá, Colombia., Valderrama-Rios MC; Universidad Nacional de Colombia, School of Medicine, Department of Internal Medicine, Bogotá, Colombia., Cortés JA; Universidad Nacional de Colombia, School of Medicine, Department of Internal Medicine, Bogotá, Colombia; Hospital Universitario Nacional de Colombia, Infectious Diseases Unit, Bogotá, Colombia.
المصدر: The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases [Braz J Infect Dis] 2023 Sep-Oct; Vol. 27 (5), pp. 102805. Date of Electronic Publication: 2023 Sep 27.
نوع المنشور: Meta-Analysis; Systematic Review; Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Editora Country of Publication: Brazil NLM ID: 9812937 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1678-4391 (Electronic) Linking ISSN: 14138670 NLM ISO Abbreviation: Braz J Infect Dis Subsets: MEDLINE
أسماء مطبوعة: Publication: 2010- : Rio de Janeiro : Elsevier Editora
Original Publication: Salvador, Bahia, Brazil : Contexto, c1997-
مواضيع طبية MeSH: Cytomegalovirus Infections*/prevention & control , Cytomegalovirus Infections*/diagnosis , HIV Infections*/complications , HIV Infections*/drug therapy, Adult ; Humans ; Antiviral Agents/therapeutic use ; Cytomegalovirus ; Viremia/complications ; Viremia/drug therapy ; Viremia/prevention & control
مستخلص: Introduction: Cytomegalovirus end-organ-disease (CMV EOD) is still a major cause of debilitating illness in people living with HIV, especially in developing countries.
Objective: To evaluate the efficacy and safety of preemptive therapy against CMV EOD in HIV-positive adults with CMV viremia.
Methods: Systematic review of clinical trials by searching electronic databases and clinical trial registries, screening and selection of references, data extraction and assessment of risk of bias. The results were presented in a narrative synthesis. Aggregated analyzes for dichotomous outcomes were reported as odds ratios with 95 % Confidence Intervals.
Results: Four RTC were included. A reduction in the risk of CMV EOD with preemptive therapy was found OR=0.49 (95 % CI 0.31‒0.76). We did not identify significant differences for all-cause mortality, adverse events, and withdrawal of the therapy secondary to adverse events.
Conclusions: Preemptive therapy could be a potential option for preventing CMV EOD in people living with HIV.
Competing Interests: Conflicts of interest JAC and MCV have received research grants from Pfizer, through the International Society of Infectious Diseases. The other authors have no conflict of interests to declare.
(Copyright © 2023 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. All rights reserved.)
فهرسة مساهمة: Keywords: Cytomegalovirus; Efficacy; HIV; Preemptive therapy; Safety; Systematic review
المشرفين على المادة: 0 (Antiviral Agents)
تواريخ الأحداث: Date Created: 20230930 Date Completed: 20231102 Latest Revision: 20231102
رمز التحديث: 20231102
مُعرف محوري في PubMed: PMC10551618
DOI: 10.1016/j.bjid.2023.102805
PMID: 37777185
قاعدة البيانات: MEDLINE
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا